Argent Trust Co Acquires Shares of 1,924 DexCom, Inc. (NASDAQ:DXCM)

Argent Trust Co acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM – Get Rating) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,924 shares of the medical device company’s stock, valued at approximately $218,000.

A number of other hedge funds have also recently bought and sold shares of the business. Centaurus Financial Inc. grew its position in shares of DexCom by 5.5% in the 1st quarter. Centaurus Financial Inc. now owns 1,236 shares of the medical device company’s stock worth $632,000 after acquiring an additional 64 shares in the last quarter. Fulton Bank N.A. grew its position in shares of DexCom by 3.7% in the 4th quarter. Fulton Bank N.A. now owns 2,674 shares of the medical device company’s stock worth $303,000 after acquiring an additional 95 shares in the last quarter. RMR Wealth Builders grew its position in shares of DexCom by 1.8% in the 3rd quarter. RMR Wealth Builders now owns 5,442 shares of the medical device company’s stock worth $438,000 after acquiring an additional 98 shares in the last quarter. Ascent Group LLC grew its position in shares of DexCom by 2.1% in the 3rd quarter. Ascent Group LLC now owns 4,778 shares of the medical device company’s stock worth $577,000 after acquiring an additional 98 shares in the last quarter. Finally, Jaffetilchin Investment Partners LLC grew its position in shares of DexCom by 7.7% in the 1st quarter. Jaffetilchin Investment Partners LLC now owns 1,412 shares of the medical device company’s stock worth $440,000 after acquiring an additional 101 shares in the last quarter. Institutional investors and hedge funds own 94.01% of the company’s stock.

Insider Transactions at DexCom

In other news, CEO Kevin R. Sayer sold 38,464 shares of the business’s stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $109.94, for a total value of $4,228,732.16. Following the sale, the chief executive officer now owns 331,337 shares of the company’s stock, valued at approximately $36,427,189.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Jereme M. Sylvain sold 2,400 shares of DexCom stock in a transaction on Monday, May 22nd. The stock was sold at an average price of $117.58, for a total value of $282,192.00. Following the transaction, the chief financial officer now directly owns 74,711 shares in the company, valued at approximately $8,784,519.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 38,464 shares of DexCom stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $109.94, for a total value of $4,228,732.16. Following the completion of the transaction, the chief executive officer now owns 331,337 shares in the company, valued at $36,427,189.78. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 141,835 shares of company stock valued at $16,443,758. Corporate insiders own 0.41% of the company’s stock.

DexCom Stock Down 1.8 %

Shares of DexCom stock opened at $114.61 on Friday. The business’s fifty day moving average price is $117.86 and its two-hundred day moving average price is $114.51. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.02 and a quick ratio of 1.82. The company has a market capitalization of $44.43 billion, a P/E ratio of 163.73 and a beta of 1.16. DexCom, Inc. has a 1-year low of $67.11 and a 1-year high of $126.44.

DexCom (NASDAQ:DXCM – Get Rating) last posted its quarterly earnings data on Thursday, April 27th. The medical device company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.02. DexCom had a return on equity of 18.29% and a net margin of 9.68%. The company had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $720.52 million. During the same quarter in the previous year, the business earned $0.08 EPS. The company’s quarterly revenue was up 1085.0% compared to the same quarter last year. As a group, research analysts forecast that DexCom, Inc. will post 1.06 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Raymond James boosted their price objective on DexCom from $138.00 to $140.00 in a research report on Friday, April 28th. TheStreet upgraded DexCom from a “c+” rating to a “b” rating in a research report on Friday, May 5th. Wolfe Research assumed coverage on DexCom in a research report on Thursday, January 26th. They set an “outperform” rating and a $121.00 price objective for the company. Cowen boosted their price objective on DexCom from $114.00 to $125.00 and gave the company an “outperform” rating in a research report on Friday, February 10th. Finally, StockNews.com assumed coverage on DexCom in a research report on Thursday, May 18th. They set a “buy” rating for the company. Two research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $126.81.

About DexCom

(Get Rating)

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.